Intervention effect of berberine on expressions of TNF-α and receptor type I in Aβ25-35-induced inflammatory reaction in SH-SY5Y cell lines

Zhongguo Zhongyao Zazhi

Volumn 38, Issue 9, 2013, Pages 1327-1330

  Xu, Jing ^a   Zhang, Hong ^a   Yang, Fan ^a   Yu, Jin Xin ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid peptide; Berberine; Inflammatory reaction; Tumor necrosis factor ; Tumor necrosis factor type I receptor

Indexed keywords

BERBERINE; INDOMETACIN; LACTATE DEHYDROGENASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IN VITRO STUDY; INFLAMMATION; LOW DRUG DOSE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY;

AMYLOID BETA-PEPTIDES; BERBERINE; CELL LINE; HUMANS; INFLAMMATION; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-1 TYPE I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879160194     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20130913     Document Type: Article

References (16)

1. Breitner J C. NSAIDs and Alzheimer's disease: how far to generalize from trial[J]. Lancet Neurol, 2003, 2(9): 527.
2. 2011, 7(2): 51.
3. 2008, 24(5): 925.
4. Halliday G, Robinson S R, Shepherd C, et al. Alzheimer'sdisease and inflammation: a review of cellular and therapeutic mechanisms[J]. Clin Exp Pharmacol Physiol, 2000, 27(1/2): 1.
5. Ringheim G E, Szczepanik A M, Petko W, et al. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex[J]. Brain Res Mol Brain Res, 1998, 55(1): 35.
6. Li Y, Liu L, Kang J, et al. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholines-terase activity and mRNA expression[J]. J Neurosci, 2000, 20(1): 149.
7. Sheng J G, Zhu S G, Jones R A, et al. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo[J]. Exp Neurol, 2000, 163(2): 388.
8. Hickey W F. Leukocyte traffic in the central nervous system: the participants and their roles[J]. Semin Immunol, 1999, 11(2): 125.
9. Teeling J L, Perry V H. Systemic infection and in flammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms[J]. Neuroscience, 2009, 158(3): 1062.
10. Giovannini M G, Scali C, Prosperi C, et al. Beta-amyloidinduced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway[J]. Neurobiol Dis, 2002, 11(2): 257.
11. Wang X, Wang R, Xing D, et al. Kinetic difference of berberine between hippocampus and plasma in rat after intravenous admini-stration of Coptidis Rhizoma extract [J]. Life Sci, 2005, 77(24): 3058.
12. Kulkarni S K, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders [J]. Phytother Res, 2010, 24(3): 317.
13. 2008, 39(9): 1351.
14. Mayhan W G. Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier[J]. Brain Res, 2002, 927(2): 144.
15. Wong D, Prameya R, Dorovini-Zis K. In vitro adhesion and migration of T lymphocytes across monolayers of human brain microvessel endothelial cells: regulation by ICAM-1, VCAM-1, E-selectin and PECAM-1[J]. J Neuropathol Exp Neurol, 1999, 58(2): 138.
16. 2008, 24(9): 776.